XML 48 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated income statements - EUR (€)
€ in Millions, shares in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Profit (loss) [abstract]      
Net sales € 42,997 € 37,761 € 36,041 [1]
Other revenues 2,392 1,414 1,328 [1]
Cost of sales (13,695) (12,255) (12,159) [1]
Gross profit 31,694 26,920 25,210 [1]
Research and development expenses (6,706) (5,692) (5,530) [1]
Selling and general expenses (10,492) (9,555) (9,391) [1]
Other operating income 1,969 859 697 [1]
Other operating expenses (2,531) (1,805) (1,415) [1]
Amortization of intangible assets (2,053) (1,580) (1,681) [1]
Impairment of intangible assets 454 (192) (330) [1]
Fair value remeasurement of contingent consideration 27 (4) 124 [1]
Restructuring costs and similar items (1,336) (820) (1,089) [1]
Other gains and losses, and litigation (370) (5) 136 [1]
Gain on Regeneron investment arising from transaction of May 29, 2020 0 0 7,382 [1]
Operating income 10,656 8,126 14,113 [1]
Financial expenses (440) (368) (388) [1]
Financial income 206 40 53 [1]
Income before tax and investments accounted for using the equity method 10,422 7,798 13,778 [1]
Income tax expense (2,006) (1,558) (1,807) [1]
Share of profit/(loss) from investments accounted for using the equity method 68 39 359 [1]
Net income 8,484 6,279 [2] 12,330 [3]
Net income attributable to non-controlling interests 113 56 [2] 36 [2],[4]
Net income attributable to equity holders of Sanofi € 8,371 € 6,223 [2] € 12,294 [1]
Average number of shares outstanding (in shares) 1,251.9 1,252.5 1,253.6 [1]
Average number of shares after dilution (in shares) 1,256.9 1,257.9 1,260.1 [1]
Basic earnings per share (in euros per share) € 6.69 € 4.97 € 9.81 [1]
Diluted earnings per share (in euros per share) € 6.66 € 4.95 € 9.76 [1]
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[2] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[4] (j)    Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.